Delivery Order SPE2DB20D1100-SPE2DB25FE6S5
- Not listed
- The Defense Logistics Agency awarded a $2,348.65 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, with an ultimate completion date of June 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $1,227.36 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, with an ultimate completion date of August 29, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order fulfillment. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters and primary pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,770.53 for Lantus SoloStar 100 Unit/mL 3mL insulin pens on August 11, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by August 12, 2025. The products will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary operations facility. This delivery order is issued under...
- The Defense Logistics Agency awarded a $1,668.59 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML 3ML insulin pens, with an ultimate completion date of September 9, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader pharmaceutical supply relationship...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,033.47 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. The contract was competitively awarded without set-aside designation under a firm fixed-price arrangement, with performance scheduled for completion by August 18, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a $4,038.26 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens on June 13, 2025, with an ultimate completion date of June 16, 2025. This firm fixed-price, competitively awarded contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,022.80 to supply Lantus SoloStar 100 Unit/mL 3mL insulin pens, with an ultimate completion date of August 29, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded through competitive procedures. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,534.20 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens on June 26, 2025, with completion scheduled for June 27, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal medical procurement needs. The order will be fulfilled at the company's...
- The Defense Logistics Agency awarded a $1,200.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML 3ML insulin pens, with an ultimate completion date of September 4, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen, headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $1,457.49 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, with an ultimate completion date of August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery transaction under AmerisourceBergen's existing pharmaceutical supply framework. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE6S5Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,673.20 to supply Lantus SoloStar 100 Unit/mL 3mL insulin pens, with a completion date of September 16, 2025. This non-set-aside, competitively awarded contract employs firm fixed price terms and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery order operates under AmerisourceBergen's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical supply vehicle for military healthcare programs. AmerisourceBergen, a major pharmaceutical distributor and critical federal medical procurement vendor, supplies an extensive portfolio of brand-name and generic medications, vaccines, and medical devices across multiple therapeutic categories to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's consistent performance under competitively awarded contracts demonstrates its capability to meet federal medical supply requirements across varying transaction values and product categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/15/25 |